Audiologists have known about the ototoxicity of quinine (and its derivatives) and antibiotics (macrolide and aminoglycoside) for decades. But we have never seen the combined use of two drugs, each with known ototoxic potential, being used as an intervention strategy for the coronavirus pandemic (COVID-19).
In an effort to combat the coronavirus (COVID-19), front-line physicians are repurposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.
At the present time, it is not known if hearing loss and/or tinnitus will be a late onset side effect of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients.
Recent Posts
How Do Animals Perceive Music?
Music can be defined as vocal, instrumental, or mechanical sounds, with rhythm, melody or harmony, and often, an expression of human emotion. Music can transcend…
‘Eye’ on Health: AI Detects Dizziness and Balance Disorders Remotely
Interesting research led by audiologist Ali Danesh, PhD, at Florida Atlantic University (FAU) helped develop a novel, proof-of-concept tool to help identify nystagmus using a…
Rizatriptan vs. Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial
Jeffrey Staab, MD, and colleagues studied the effectiveness of rizatriptan as a treatment option for vestibular migraine. Their research included 134 patients between the ages of…